| Drug Program | Target/Delivery | Therapeutic Area | Discovery | IND enabling | Phase 1a | Phase 1b | ||
|---|---|---|---|---|---|---|---|---|
| Targeted Protein Degradation | ||||||||
| NX-2127 Degrader | BTK + IKZF (Oral) | B-cell malignancies |
| |||||
| NX-5948 Degrader | BTK (Oral) | B-cell malignancies |
| |||||
| NX-0479 / GS-6791 Degrader | IRAK4 (Oral) | Rheumatoid arthritis and other inflammatory diseases |
 | |||||
| Drug Program | Target/Delivery | Therapeutic Area | Discovery | IND enabling | Phase 1a | Phase 1b | ||
| Targeted Protein Elevation | ||||||||
| NX-1607 Inhibitor | CBL-B (Oral) | Immuno-oncology |
| |||||
| Drug Program | Target/Delivery | Therapeutic Area | Discovery | IND enabling | Phase 1a | Phase 1b | ||
| Discovery Pipeline | ||||||||
| Wholly Owned | 5 targets | Undisclosed |
| |||||
| Gilead Sciences | 4 Targets | Undisclosed |
| |||||
| Sanofi | 5 Targets | Undisclosed |
| |||||
| Targeted Protein Degradation | NX-2127 DegraderBTK + IKZF (Oral) - B-cell malignancies |
Preclinical IND-Enabling Phase 1a Phase 1b |
|
| NX-5948 DegraderBTK (Oral) - B-cell malignancies |
Preclinical IND-Enabling Phase 1a Phase 1b |
|
| NX-0479 / GS-6791 DegraderIRAK4 (Oral) - Rheumatoid arthritis and other inflammatory diseases |
Preclinical IND-Enabling Phase 1a Phase 1b |
|
| Targeted Protein Elevation | NX-1607 InhibitorCBL-B (Oral) - Immuno-oncology |
Preclinical IND-Enabling Phase 1a Phase 1b |
|
| Discovery Pipeline | Wholly Owned 5 targets - Undisclosed |
Preclinical IND-Enabling Phase 1a Phase 1b |
|
| Gilead Sciences4 Targets - Undisclosed |
Preclinical IND-Enabling Phase 1a Phase 1b |
|
| Sanofi5 Targets - Undisclosed |
Preclinical IND-Enabling Phase 1a Phase 1b |
|
'